Rigel Pharmaceuticals, Inc.
(NASDAQ : RIGL)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
-2.13%199.081.3%$749.78m
GILDGilead Sciences, Inc.
-2.66%62.510.9%$372.82m
CELGCelgene Corporation
-1.80%93.991.3%$323.19m
ALXNAlexion Pharmaceuticals, Inc.
-6.61%115.332.0%$295.67m
ILMNIllumina, Inc.
-3.17%279.443.5%$272.03m
BIIBBiogen Inc.
-2.68%225.851.3%$258.17m
VRTXVertex Pharmaceuticals Incorporated
-2.20%180.181.9%$251.48m
EXASExact Sciences Corporation
-0.77%116.9624.1%$238.08m
REGNRegeneron Pharmaceuticals, Inc.
-2.77%286.852.6%$193.57m
AAgilent Technologies, Inc.
-3.01%69.581.6%$188.95m
SRPTSarepta Therapeutics, Inc.
-1.54%93.6114.7%$184.96m
BMRNBioMarin Pharmaceutical Inc.
-2.12%75.764.3%$97.12m
INCYIncyte Corporation
-4.27%81.912.5%$90.56m
GHDXGenomic Health, Inc.
-0.35%73.261.8%$81.69m
NBIXNeurocrine Biosciences, Inc.
0.36%97.595.0%$71.75m

Company Profile

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. Its products include Tavalisse, Fostamatinib and R835. The company was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.